en
Professional article
English

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

Published inAnnals of the rheumatic diseases, vol. 72, no. 11, p. 1786-1792
Publication date2013
Abstract

Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood concentration ([HCQ]) varies widely between patients and is a marker and predictor of SLE flares. This prospective randomised, double-blind, placebo-controlled, multicentre study sought to compare standard and adjusted HCQ dosing schedules that target [HCQ] ≥1000 ng/ml to reduce SLE flares.

Keywords
  • Adult
  • Antirheumatic Agents/administration & dosage/blood
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Monitoring/methods
  • Female
  • France
  • Humans
  • Hydroxychloroquine/administration & dosage/blood
  • Lupus Erythematosus, Systemic/drug therapy
  • Male
  • Middle Aged
  • Prospective Studies
  • Treatment Outcome
Affiliation Not a UNIGE publication
Citation (ISO format)
COSTEDOAT-CHALUMEAU, Nathalie et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). In: Annals of the rheumatic diseases, 2013, vol. 72, n° 11, p. 1786–1792. doi: 10.1136/annrheumdis-2012-202322
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0003-4967
489views
0downloads

Technical informations

Creation11/07/2015 2:57:00 PM
First validation11/07/2015 2:57:00 PM
Update time03/14/2023 11:57:15 PM
Status update03/14/2023 11:57:14 PM
Last indexation01/16/2024 7:46:54 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack